Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 16/20 | 0.68 |
| ▸ | TTK | P33981 | 4/20 | 0.66 |
| ▸ | CSF1R | P07333 | 2/20 | 0.66 |
| ▸ | AURKA | O14965 | 2/20 | 0.59 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.59 |
| ▸ | CDK2 | P24941 | 1/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.54 |
| ▸ | MTOR | P42345 | 2/20 | 0.54 |
| ▸ | PDE9A | O76083 | 2/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1781558 | 0.86 | PRKDC (0.69) | PRKDCTTKCSF1RAURKACCNA2 | |
| SCHEMBL1781846 | 0.81 | PRKDC (0.62) | PRKDCTTKCSF1RAURKACCNA2 | |
| SCHEMBL1782576 | 0.81 | CDK4 (0.67) | PRKDCTTKCSF1RAURKACCNA2 | |
| SCHEMBL1781331 | 0.80 | CDK4 (0.71) | PRKDCTTKCSF1RAURKACCNA2 | |
| SCHEMBL1782804 | 0.80 | PRKDC (0.69) | PRKDCTTKCSF1RAURKACCNA2 | |
| SCHEMBL1780821 | 0.80 | PRKDC (0.63) | PRKDCTTKCSF1RAURKACCNA2 | |
| SCHEMBL1781620 | 0.80 | CDK4 (0.68) | PRKDCTTKCSF1RAURKACCNA2 | |
| SCHEMBL1781375 | 0.80 | PRKDC (0.71) | PRKDCTTKCSF1RAURKACCNA2 | |
| SCHEMBL23948252 | 0.79 | PRKDC (1.00) | PRKDCTTKCSF1RAURKACCNA2 | |
| SCHEMBL29502021 | 0.79 | PRKDC (1.00) | PRKDCTTKCSF1RAURKACCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | US | disclosed |
| EP-2212326-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009024824-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BUB1, BUB1B, TTBK1 | PRKDC 163/4885TTK 4/4885CSF1R 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.